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Abstract
Background: In the era of rapid dolutegravir rollout, concerns about neural tube defects have complicated the health
systems response among women of childbearing potential. This qualitative study, which was nested within the DolPHIN-2
clinical trial, examined the current and future health system opportunities and challenges associated with the transition to
dolutegravir-based regimen as first line antiretroviral therapy among women of childbearing potential in South Africa and
Uganda.
Method: Semi-structured in-depth interviews with members of antiretroviral therapy guideline development groups and
affiliates were conducted. Thirty-one participants were purposively selected for the study, including senior officials from
the Ministry of Health and National Drug Regulatory Authority in Uganda and South Africa as well as health-sector
development partners, activists, researchers and health workers. A thematic approach was used to analyse the data.
Findings: Despite differences in health system contexts, several common challenges and opportunities were identified
with the transition among women of childbearing potential in South Africa and Uganda. In both contexts national
stakeholders identified challenges with ensuring gender equity in roll out due to the potential teratogenicity of
dolutegravir, paucity of data on dolutegravir use in pregnancy, potential stock out of effective contraceptives, poorly
integrated contraception services, and limited pharmacovigilance in pregnancy. Participants identified opportunities
that could be harnessed to accelerate the transition, including high stakeholder interest and commitment to transition,
national approval and licensure of a generic tenofovir/lamivudine/dolutegravir regimen, availability of a network of
antiretroviral therapy providers, and strong desire among women for newer and more tolerable regimens.
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Conclusion: The transition to dolutegravir-based regimens has the potential to strengthen health systems in low- and
middle-income countries to engender equitable access to optimised antiretroviral regimen among women. There is
the need for a multi-sectoral effort to harness the opportunities of the health systems to addresses the bottlenecks to
the transition and initiate extensive community engagement alongside individual and institutional capacity
strengthening. Improvements in pregnancy pharmacovigilance and counselling and family planning services are critical
to ensuring a successful transition among women of childbearing potential.
Keywords: Health system strengthening, Dolutegravir-based regimen, Women of childbearing potential, Qualitative
study, Uganda, South Africa
Background
Since 2016 there has been a concerted effort to imple-
ment dolutegravir-based first line antiretroviral therapy
regimens in low- and middle-income countries (LMICs)
following the World Health Organisation (WHO) guide-
lines releases in 2016 [1] and 2018 [2]. The impetus for
transition to dolutegravir reflects its advantages over
current first line efavirenz-based regimens, including im-
proved viral suppression and tolerability as well as a
higher genetic barrier to resistance [3, 4]. Programmatic-
ally, large-scale rollout of dolutegravir has potential to
increase harmonisation, simplify drug procurement and
lower costs [2]. Recent modelling studies indicate overall
public health benefits from wider dolutegravir use [5, 6]
despite its potential association with neural tube defects
when used periconception [7].
After initial enthusiasm a more cautious approach to
dolutegravir use among women of childbearing potential
was recommended in 2018. This included avoiding use
in the periconception period, ensuring reliable contra-
ception and informed choice [2]. Use in second and
third trimesters of pregnancy was not contraindicated.
In July 2019, WHO downgraded the risk of neural tube
defects following new evidence and recommended
dolutegravir as a preferred regimen for women of child-
bearing potential, although the caution remains [8].
Many LMICs have either adopted or planning to switch to
dolutegravir-based regimens for first line treatment [9]. It is
estimated that by 2021 approximately 15 million people
would be using dolutegravir-based regimens, with non-
nucleoside reverse-transcriptase inhibitor-based regimens
being rapidly replaced [10]. South Africa and Uganda have
revised their ART guidelines to transition to dolutegravir-
based first-line HIV regimens and away from efavirenz-
containing regimens. These countries have high rates of
HIV prevalence (South Africa 20.4% and Uganda 5.7%),
people on antiretroviral treatment (South Africa 4.4million;
Uganda 940,000) [11], and pre-treatment resistance to non-
nucleoside reverse-transcriptase inhibitor-based regimens
(Uganda 15.9% and South Africa 23.6%) [12]. In Uganda, na-
tional roll-out of dolutegravir-based regimens commenced
in March 2018 with access initially restricted among women
of childbearing potential but later extended to include all
adults in line with new WHO guidelines [13]. In South Afri-
can guidelines published in October 2019, dolutegravir is
recommended as the preferred regimen for all adults except
in women around the time of conception and in the first tri-
mester of pregnancy. Women of childbearing potential are
encouraged to use contraception if taking dolutegravir [14].
Experience from previous transition in ART regimens
suggests that the transition process can place profound
strain on the health system, particularly in resource-
limited countries. With health systems in LMICs under-
resourced, reliant on donor-funded vertical programmes,
and care for human immunodeficiency viruses (HIV) de-
livered by lower level cadres through standardised proto-
cols, implementing the nuanced WHO approach to the
transition among women of childbearing potential could
pose significant challenges. In this study, we explored
the potential health system opportunities and challenges
to transitioning to dolutegravir-based first line regimen
among women of childbearing potential in South Africa
and Uganda. We aimed to draw lessons that would
resonate with other LMICs as they prepare to change
their first line regimen to dolutegravir-based regimen.
Methods
Study design
This study forms part of the qualitative component of
the DolPHIN-2 trial (NCT03249181) which aims to
evaluate the efficacy and safety of dolutegravir use in
pregnancy. Early results from the trial indicate that
dolutegravir is well-tolerated and achieves superior viro-
logical suppression compared to efavirenz when initiated
in late pregnancy [15]. The current study was set in
South Africa and Uganda because they are study sites
for the DolPHIN-2 trial and provide suitable contexts
for understanding LMICs health systems.
We employed a qualitative exploratory design in this
study to better understand stakeholders perspectives of
the health systems opportunities and challenges to the
transition and the context in which those perspectives
are situated [16]. In order to obtain a holistic view of the
health system, we used the WHO health system building
blocks framework to determine potential areas of impact
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by the transition to focus our investigation [17, 18]. The
approach conceptualises the health system as encom-
passing six functional components including steward-
ship, financing, information systems, human resources,
service delivery and medical products. It also under-
scores the role of communities (people) as mediators
and beneficiaries of the functions of the health system as
well as equity, efficiency, responsiveness and financial
protection as important health system goals [19]. We fo-
cused mainly on the six functional components of the
health system plus the community to ascertain the po-
tential opportunities and challenges to the transition.
Participant selection
Purposive sampling was applied to select respondents.
Given the complex and prospective nature of transition-
ing (rollout had not started during the study), we sought
to understand the potential issues through the perspec-
tives of key informants [20]. Key informant accounts
provide a generalised and summarised view of health
care system transition and are informed by previous and
current experience as well as future expectation, which
are useful for prospective studies [21]. Participants had
several years of working in their fields (Table 1) and
were mainly members of the ART guidelines technical
working group (TWG) and affiliates in South Africa and
Uganda. They included Ministry of Health (MOH) offi-
cials involved in HIV policy and programmes, clinicians,
researchers, activists, HIV development partners, and
national drug regulators (Table 1). The researchers and
MOH officials who were selected were all members of
the guidelines TWG in their respective countries; the cli-
nicians in Uganda were involved in the implementation
of a transition pilot; the regulators were responsible for
licensing and monitoring the safety of dolutegravir; and
the development partners provided funding and technical
assistance to the transition. We identified key institutions
known to be involved in the transition and invited senior
officials who were directly involved in the process to par-
ticipate. Snowball sampling was used to supplement the
initial participant list. Participants were recruited and
interviewed until no new themes emerged and saturation
was reached [22]. A total of 31 key informants participated
in the study across the two study settings.
Data collection
Data collection was conducted between January and Au-
gust 2018, at the time of participant recruitment for the
DolPHIN-2 trial. The period coincided with the releases of
preliminary results from the Tsepamo study and the WHO
safety alert on the potential association of dolutegravir use
in periconception with risk of neural tube defects [23, 24],
which may have shaped participants’ responses. Neither
study countries had started rolling out dolutegravir-based
regimens at the time of the interviews; and were in the
process of revising guidelines and preparing for transition.
Semi-structured topic guides were used to explore partici-
pants’ perceptions about current and anticipated challenges
and opportunities and how experiences from previous ART
rollouts may inform the current transition. The topic guides
initially developed by YA and MT were based on the WHO
2018 ART guidelines [2] and the WHO building block
framework. They focused on key policy and programmatic
issues in relation to the transition, including guidelines de-
velopment/revision, commodity procurement and supply,
delivery of dolutegravir based treatment, health worker cap-
acity, pharmacovigilance, and community acceptability. The
topic guides were piloted and revised iteratively as the in-
terviews evolved. All interviews were conducted in English,
either face-to-face or telephonically, by experienced senior
qualitative researchers (YA, MT, AT and TM), and audio
recorded. The interviews were complemented by a review
of literature and policy documents to provide background
information to place our findings into context. These in-
cluded ART guidelines, the South Africa National Strategic
Plan for HIV, TB and STIs (2017–2022), the Uganda Na-
tional HIV and AIDS Stratergic Plan (2015/2016–2019/
2020), and the Uganda Presidential Fast Track Action plan.
Data analysis
Audio-recorded interviews were transcribed verbatim,
with each being reviewed for completeness and accuracy.
Data were analysed in NVivo 11 software based on a
thematic approach. Themes were inductively generated
based on ideas that emerged from the data [25]. Each
transcript was read and reread by YA, AT and MT for
recurrent ideas. Codes were assigned to relevant seg-
ments of the text; similar codes were aggregated to form
Table 1 Background characteristics of study participantsa
South Africa
n (16)
Uganda
n (15)
Total
n (31)
Sector
Ministry of Health 2 2 4
Regulator 4 1 5
Researcher 7 3 10
Activist 2 3 5
Clinician 0 3 3
Development partner 1 3 4
Sex
Male 10 3 13
Female 6 12 18
Number of years working in field Range: 5–35
Median: 15.6
Age ≥ 25 years
aSome participant categories overlap due to multiple roles
Alhassan et al. BMC Health Services Research          (2020) 20:705 Page 3 of 12
themes that were then used to address the research
questions and develop coherent narratives [26]. Identi-
fied themes were categorised under key components of
the transition process (see Fig. 1). Contradictory data
identified during the analysis were initially treated as po-
tential different viewpoints; they were subjected to fur-
ther analyses to validate or refute them; validated data
were used to enrich the perspectives on the issue [27].
To ensure rigor and trustworthiness, transcripts were in-
dependently coded, compared and discussed, and a com-
mon coding framework was used [25]. Inter-rater
agreement between the analysts was moderate (Kappa
coefficient = .75), discrepancies were discussed and re-
solved by consensus at coding meetings [28]. Emerging
findings from the analysis were discussed among the au-
thors in regular qualitative research network meetings,
and reponsdent validation was ensured by presenting
draft results to the stakeholders with subsequent feed-
back integrated into the analysis.
Ethical considerations
Ethical approval for the study was obtained from ethics
review commitees of the Liverpool School of Tropical
Medicine (LSTM REC 17–087), the University of Cape
Town Faculty of Health Sciences (HREC REF: 280/2018)
and the Joint Clinical Reseach Centre in Uganda
(JC0818). Participation in the study was voluntary and
written and/or verbal informed consent was obtained
from participants before data collection. All participant
personal information and identity were removed during
analysis and reporting, and privacy and annonymity were
maintained by applying alphanumeric codes. All data
were password protected and stored on encrypted com-
puters and locked cabinets.
Results
Despite difference in health system context, participants
identified several common opportunities and challenges to
the transition to dolutegravir-based regimens among
women of childbearing potential in South Africa and
Uganda. Whilst the WHO building blocks were used to
structure our enquiry, we found that some of the themes
that emerged from the data were not clearly aligned with
the categories of the health system components and some
aspects of the health system components were more crit-
ical than others for the transition. Therefore, we presented
the findings in line with Fig. 1, which outlines key compo-
nents of the transition process and related opportunities
and challenges, enabling us to better highlight where the
WHO building blocks are particularly affected in the
Fig. 1 Potential health system opportunities and challenges to transition to dolutegravir-based regimens. Diagram outlines key elements of the
health system involved in transitioning to dolutegravir-based first line antiretroviral regimens among women of childbearing potential, and
related potential opportunities and challenges identified in South Africa and Uganda. Orange rectangle shapes represent major activities of the
transition process and the purple shapes represent auxiliary activities/elements. Arrows denote relationship between the
transition elements/activities
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transition. The key components of the transition process
include guidelines development, evidence generation, sup-
ply of medical commodities, staff capacity and service de-
livery, community acceptability, and uptake and post-
market surveillance.
Guidelines development
Stakeholder interest in transition to dolutegravir among
women
Nearly all the participants agreed that it was essential to
switch to dolutegravir-based regimens due to the numer-
ous potential benefits that it provided, especially for
women. They noted high interest and commitment to
the transition among politicians, donors, civil society
groups and providers in both countries. Several of the
MOH staff stated that they were motived by dolutegravir’s
high genetic barrier to resistance. Potential cost savings as-
sociated with widespread use of dolutegravir-based regi-
mens was particularly attractive to both national
policymakers and donors. Civil society actors were driven
by the potential direct health benefits of dolutegravir to
women, especially low side effects, rapid viral suppression,
and reduced risk of vertical transmission. Despite existing
health system challenges, most participants were optimistic
that their countries could successfully transition to
dolutegravir-based regimens (including amongst women)
due to the high stakeholder interest and experience from
previous ART regimens changes.
“Everybody is committed. … they all want to be part
and are very supportive because of its [ dolutegravir]
benefits. … Because of its potential to reduce vertical
transmission there is an interest to ensure that
women are able to access it. I’m very sure transition
is possible. This is not going to be the first time that
we have change HIV drugs … . There will definitely
be challenges but together I’m sure we can overcome
them.” (Uganda, MOH staff, P12)
Uncertainty about dolutegravir use in pregnancy
A major challenge to developing ART guidelines for the
transition in both countries was uncertainty about
dolutegravir use in pregnancy (and among women of
childbearing potential) due to potential association with
neural tube defects. There was reported long delay in re-
vising ART guidelines due to disagreement over how to
balance the public health risks and individual benefits of
dolutegravir use among women of childbearing poten-
tial. Several guidelines TWG members noted that the
debate presented ethical conundrums which they lacked
adequate information to deal with.
“How to balance the risks [of neural tube defects to
the child] and benefits [to the mother] of DTG
[dolutegravir] is a source of worry and delaying us.
… it raises ethical issues which we are not well
equipped to handle” (South Africa, Researcher, P2)
Difficulty in operationalising ‘informed choice’ and ‘reliable/
effective contraception’
While welcoming the WHO recommendation for informed
choice over dolutegravir use among women of childbearing
potential, several guidelines TWG members across both
countries reported difficulties in operationalising ‘informed
choice’ citing how hard it was to define ‘choice’ and ‘in-
formed’, and how to document informed choice. They also
expressed ambiguity over the WHO term ‘reliable/effective
contraception’ and stressed the need for greater clarity on
the term and informed by community perspectives.
“What they [WHO] say ‘reliable method of contracep-
tion’? what does it mean in practice? Is it someone say-
ing that they are not sleeping with anyone? Are
condoms a reliable method of contraception? is it inject-
ables? it is hormonal contraception? So, I think in the
end the understanding of these loaded words from a
community perspective is important” (South Africa, Re-
searcher, P6).
Pressure to transition quickly
Some MOH staff lamented over pressure from several
donors and patient advocacy organisations to transition
quickly and allow dolutegravir use among women of
childbearing potential even when the health systems
were not prepared and lacked sufficient evidence on the
safety of dolutegravir use in pregnancy.
“Unfortunately, we can’t wait [for the evidence on the
safety of dolutegravir] even when we are limited by
that because there is a lot of pressure from civil society
as well as PEPFAR. PEPFAR has given us a fair
amount of money to move towards a dolutegravir-
based [regimen].” (South Africa, MOH staff, P1)
Evidence generation
Paucity of evidence on dolutegravir use in pregnancy
Lack of data on the safety of dolutegravir in pregnancy
was identified as a major barrier to transition among
women. In South Africa, insufficient safety data in preg-
nancy was widely mentioned as a key reason for the delay
in the national rollout. Several guidelines TWG members
identified the Tsepamo study as their main source of
safety data on dolutegravir but noted it was inadequate
due to being an observational study. Participants
expressed the need for more clinical trial data.
“ … neural tube defect is making life difficult for us
as we develop the guidelines. It is difficult to make a
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decision on how to roll it out among women. We
only have the Botswana data to work with but that
one has its challenges. We need more trial data. … .
it should cover all aspects of pregnancy.” (South Af-
rica, MOH staff, P7)
Further, participants identified a lack of community and
operational evidence to inform the transition. Unlike
Uganda, no pilot study had been conducted in South Africa
to support rollout, leading to guidelines TWG members
calling for data on the expectations, values and preferences
of women living with HIV on dolutegravir treatment.
Whilst both countries had previously implemented
ART transition (e.g. replacement of stavudine and the
change from nevirapine to efavirenz), there was also a
sense that the current transition with its emphasis on
nuanced treatment services among women (due to
the potential teratogenicity of dolutegravir) was differ-
ent and needed to be informed by more dolutegravir-
specific data. Participants across both countries be-
lieved that evidence generation was being hindered by
the rapid pace of the transition.
“We are likely to face problems, just like we have done
in the past [transition] because we haven’t taken our
time to consult with those who will be affected. …
there is pressure to get it [transition] started as soon
as possible.” (Uganda, MOH staff, P5).
Supply of medical commodities
Availability of TLD
Participants were optimistic about adequate supply of
dolutegravir-based regimen during the transition. Both
countries had planned to use generic fixed dose dolute-
gravir regimen, TLD (tenofovir/lamivudine/dolutegravir),
which had received regulatory approval at the national
level. With support from development partners Uganda
had procured large quantities of TLD from the inter-
national market which the MOH staff noted would be
sufficient in the medium term of the transition. South
Africa had a relatively well-developed pharmaceutical
industry compared with Uganda, and policymakers
expected it to be able to meet domestic demand for
TLD.
“We already have large quantities of TLD that we pur-
chased a while ago with the help of our partners. … I
don’t think there will be problem with supply of TLD
now, we have enough.” (Uganda, MOH staff, P4)
“I am optimistic that our local industry will be cap-
able of producing the needed amount of TLD for the
transition.” (South Africa, MOH staff, P7)
Additionally, existing supply chain systems for ART
and other medical supplies were deemed to be key op-
portunities to accelerate the transition in both countries.
Potential stockout of contraceptives
Participants reported frequent shortage of long-acting
contraceptives in public health facilities in both coun-
tries as a potential barrier to the transition among
women. They anticipated an increased demand for long-
acting contraceptives following the rollout of
dolutegravir-based regimen but noted no additional pro-
curement arrangements had been made to increase sup-
ply. Most reported a lack of sufficient contraceptive
options for HIV positive women who are often contrain-
dicated for certain contraceptives.
“nothing has been done on the contraceptive side … .
I think the thinking is that it would be taken care of
by what is currently available. We are likely to ex-
perience shortages … Most facilities in the hard to
reach areas do not have enough family planning op-
tions; they only have condoms … . Some positive can-
not use certain contraceptives, so we need to improve
options.” (Uganda, MOH staff, P12)
Part of the concern about contraceptive stockout was
linked with funding shortage, which some participants in
Uganda noted was partly due to some donors’ disinterest
in contraception services.
“The sector is already chronically underfunded... The
problem is that some of our major donors are not in-
terested in contraception. So you find that they will
provide money for HIV but not for family planning.”
(Uganda, MOH staff, P12)
Weak stock management system
Regimen change requires an effective stock management
system to minimise drug shortage and wastage. In
South Africa, poor stock management at sub-national
levels was reported to often create stockout of ARVs
in health facilities. Participants emphasised the need
for efficient systems to ensure proper forecasting and
availability of ART and contraceptive commodities in
health facilities.
“It doesn't really matter whether there is enough drug
at the depot it has to be at the facility. The problem
with our system is that … there has been a lot of diffi-
culty with understanding where the stock is. At the
district level you think there should be enough stock,
but everything is sitting in clinic A, whereas clinic B
has no drug.” (South Africa, MOH staff, P6)
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Several MOH staff across both countries were also
concerned that the WHO recommendation for a choice-
based approach to ART among women of childbearing
potential involving the use of either TLD or TLE/TEE
(tenofovir/lamivudine/efavirenz; tenofovir/emtricitabine/
efavirenz) would make it difficult to forecast actual com-
modity needs of the transition to ensure adequate
supply.
“If you are saying that you are going to give women
a choice … , how do you quantify choice? How do
you say that for every 5 women who come into the
facility 5 of them will choose to have dolutegravir?
it’s difficult to plan to ensure that the right commod-
ities are available.” (Uganda, Clinician, P6).
Staff capacity and service delivery
Availability of ART service providers
Despite the above shortcomings, participants identified
the availability of a network of ART service providers
across the countries as a major opportunity for the tran-
sition. A key advantage noted was providers experience
with previous ART regimen transitions. Whilst recognis-
ing their deficiencies, participants were optimistic that
ART service providers could be empowered with im-
proved infrastructure, equipment, personnel and training
to accelerate the transition to dolutegravir.
“We are lucky we already have our service providers;
they are everywhere in the country, and they have
experience with previous switch. All we need to do
now is to train them in the new guidelines and give
them resources and they will be ready to roll it out.”
(Uganda, MOH staff, P11).
Low capacity of health workers
Participants reported human resource crisis in the health
sectors of both countries. Transition to dolutegravir-
based regimen requires greater human resource capacity
to deal with the extensive patient education, counsel-
ling and monitoring needs associated with treatment
among women of childbearing potential. However,
with existing acute shortage of health personnel and
high client load in the health systems of South Africa
and Uganda, there was concern about inadequate
health workers for the transition and a potential
worsening of ART service standard if the transition is
implemented.
“ … with our client load, low staffing norms, limited
motivation of health workers, it will be hard for us
to implement the counselling they [WHO] are asking
for … . This is a big problem for the quality of ART
service and the roll-out.” (Uganda, Clinician, P10).
Further, participants recognised that most health
workers involved in HIV care did not have the required
skill set for dolutegravir-based treatment. Knowledge of
current ART regimens and treatment protocols were
deemed to be insufficient due to the potential risks of
dolutegravir and the need for nuanced care for women
of childbearing potential.
“There hasn’t been training for about 11 or 12 years
within the South African programme. We have just
kind of been bashing along … . The switches we have
had have not been particularly complicated. This
one is going to be much more complicated.” (South
Africa, Researcher, P2).
Participants suggested the need for comprehensive
training (rather than the usual orientation), including
training in contraception for ART providers. They also
suggested the need for dolutegravir-based treatment
guidelines to be simplified to enable lower cadre health
workers to implement.
Weak integration between HIV and contraception services
Effective contraception is recommended by the WHO
for optimal dolutegravir use among women of childbear-
ing potential. However, nearly all participants stated that
family planning services in both countries were under-
funded and deficient, characterised by frequent contra-
ceptive shortage and lack of service in rural areas.
Crucially, they identified weak integration between HIV
and family planning services in both countries. South
Africa was noted to have relatively better service com-
pared with Uganda, although it was feared that the
drawbacks could undermine the transition in both
countries.
“we need to make sure that contraception services
are available in the ART clinics and that women are
using them. That has been a weakness because in
our health facilities the family planning clinic is usu-
ally on its own and ART clinic is on its own. … with-
out integration how would you know if it is safe for
woman to use dolutegravir?” (Uganda, Clinician,
P9).
Community acceptability and uptake
Women’s desire for a regimen change
Nearly all participants across both countries identified
that there was greater desire among women living with
HIV for a regimen change due to the side effects of the
current non-nucleoside reverse-transcriptase inhibitor-
based regimens. They noted that this would promote
greater community uptake of dolutegravir, being a better
tolerated and more effective regimen, when it is rollout.
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However, there were concerns expressed among some
MOH participants about how to meet community ex-
pectations with a higher demand.
“I think it will be wowed by the community … . You
know they have been complaining about the current
drugs and are calling for something better. Now the
problem is how to meet the high demand that would
follow.” (South Africa, MOH official, P7)
Limited knowledge about dolutegravir among women
Community awareness about dolutegravir was deemed
to be essential for acceptability and uptake. However,
not only was awareness about dolutegravir noted to be
low in both countries, participants also reported of wide-
spread misinformation in communities about dolutegra-
vir due to publicity around the possible association with
neural tube defects.
“uptake will depend on how much people know. I
mean it is easy for us here [in the city], but at the
grassroots level … where they may not have access to
all the information … they may say I am on my Efa-
virenz I am doing fine so I don’t need to change.”
(Uganda, Development Partner, P1).
High illiteracy among women was a key concern among
participants, which was noted would hinder women’s abil-
ity to make optimal treatment choice. Many activists thus
stressed the need for greater access to information about
the risks and benefits of dolutegravir to engender better
decision making on ART among women.
“ … the African woman has been presented for so
long that … . … ‘Oh, they will not be able to decide
for themselves’. So, provide the choice with informa-
tion so that they know and decide for themselves.”
(South Africa, Activist, P35)
Potential resistance to dolutegravir use in pregnancy
Several participants (mostly activists and development
partners) were concerned that the potential risk of
neural tube defects would discourage vulnerable groups
with limited information from using dolutegravir. They
feared that most men would prevent their spouses from
using dolutegravir-based regimens due the potential
risks in pregnancy.
“People are taking the neural tube defects news ser-
ious and because of that they will reject dolutegravir.
… you know in our culture pregnancy and children
are very important. … even if the woman likes it,
the man will tell her not to use it.” (Uganda, Ac-
tivist, P7)
Post-market surveillance
Limited systems for pharmacovigilance in pregnancy
There was widespread recognition of the need for the
rollout of dolutegravir-based regimens to be accompan-
ied by intensive pharmacovigilance in pregnancy due to
the potential teratogenicity of the drug. However, exist-
ing pharmacovigilance systems in South Africa and
Uganda were noted to be inadequate for effective tox-
icity monitoring in pregnancy. Both countries relied
heavily on general pharmacovigilance (spontaneous
reporting system) for ART and constrained by severe
underreporting, low funding and poor coordination.
“our pharmacovigilance system in this country is not
efficient enough to follow up the roll out of these
drugs [ARVs] in pregnant women. … we rely mainly
on spontaneous reporting, even for ART.” (Uganda,
Regulator, P11).
South Africa had a limited pregnancy pharmacovigi-
lance system for ART in the form of two provincial level
pregnancy registries. However, participants noted that
the registries were too expensive to scale up nationally,
lacked effective mechanisms for analyses, interpretation
and use of the data, and did not cover postpartum risks.
Some regulators in Uganda expressed the desire for a
pregnancy registry to support the rollout of dolutegravir
in the country but noted they lacked financial resources
and technical expertise to establish one.
“I am always preaching for pregnancy registry espe-
cially now that DTG is coming. But whenever I bring
it up [in meetings with the ministry] they will say
there is no money to do it. … they will say it is our
remit, but they will not provide the funds. … we need
help like technical expertise” (Uganda, Regulator,
P11).
Discussion
This study explored the health system implications of
introducing dolutegravir-based regimens among women
of childbearing potential in two resource-limited settings
in sub-Saharan Africa. Whilst transition to a
dolutegravir-based first line regimen is fraught with
challenges, it presents opportunities for health system
strengthening. Challenges identified across the two
countries include potential gender inequity, limited data
on community preferences and safety of dolutegravir use
in pregnancy, weak stock management system and po-
tential stock out of effective contraceptives, limited
health worker capacity, weak integration between HIV
and contraception services, and limited pharmacovigi-
lance in pregnancy. Studies from elsewhere indicate that
these are likely to be relevant to a large number of LMIC
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contexts where HIV is endemic [3, 29]. The current pol-
itical will for transition (both from national governments
and international development partners) coupled with
existing health system resources provide opportunities
for tackling the challenges particularly in contraceptive
services and pregnancy pharmacovigilance.
Our findings revealed a tension between the rapid pace
of transition and the weak health system preparedness of
the study countries. The complexity and scale of the
transition require comprehensive planning and prepar-
ation, yet there was immense pressure from donors and
civil society organisations for health systems to transi-
tion quickly and to allow women of childbearing poten-
tial to access dolutegravir-based regimens despite health
systems being ill-prepared to implement the change in
regimen. This resulted in the development of tentative
guidelines with no robust evidence to support critical
decisions. Future transition would merit a gradual ap-
proach that allows for all the necessary institutional and
individual capacities to be strengthened and for essential
evidence to be collated to inform the transition process.
The availability of adequate robust data on dolutegra-
vir use in pregnancy is central to both policy and clinical
decisions in transition. Important data gaps were the
safety of dolutegravir use in pregnancy (especially at
periconception and early pregnancy), switching between
regimens during pregnancy, rollout implementation and
community values and preference on dolutegravir-based
treatment. Previous studies have reported gaps in evi-
dence on dolutegravir use among HIV-TB coinfected
people and among people who have not been evaluated
for drug resistance before starting treatment [10]. Whilst
both observational and clinical trial data may be useful
in addressing these gaps, our study found that health
system stakeholders are most persuaded by clinical trial
data. Data from the Tsepamo study and ongoing trials
on dolutegravir such as DolPHIN-2 may address some
of these gaps. Operational data and community feedback
from early adopter countries are also needed to facilitate
a successful transition.
Establishing an effective national pharmacovigilance
system for ART is critical for toxicity monitoring and
pregnancy safety surveillance. The results show that
stakeholders are most concerned about the risks of
dolutegravir exposure in pregnancy and lactation, sug-
gesting the need for pharmacovigilance to focus on both
areas. Spontaneous reporting systems common in most
LMICs, with their low and biased reporting, provide lim-
ited data to address the surveillance needs [30]. The
WHO pregnancy exposure registry has over the years
provided the blueprint for pregnancy pharmacovigilance
in many LMICs, including South Africa, and is useful for
delivering comprehensive data on maternal health and
ARV exposure risks in pregnancy [31]. The high uptake
of antenatal care [31] and existing clinical programmes
(e.g. antenatal care and ART) in many LMICs (including
South Africa and Uganda) are useful opportunities for
creating a pregnancy registry. However, as observed in
the interviews in South Africa and other studies [30],
such pregnancy registries are resource intensive and fail
to address risks associated with exposure in lactation.
Additionally, establishing pregnancy pharmacovigilance
systems may be constrained by limited human resource
capacity to monitor birth outcomes and toxicities, lack
of diagnostic equipment for case detection, low staff and
patient motivation to engage, limited access to antenatal
and postnatal services in rural areas, and poor reporting
systems [32]. Consequently, health systems in LMICs
may need a more pragmatic and cost-effective pregnancy
pharmacovigilance system that would yield the necessary
treatment and comparison data on dolutegravir use in
pregnancy and lactation to ascertain both long- and
short -term toxicities. The high turnover of ART regi-
men means that such a system should be amenable to
different ARV drugs and integrated into the healthcare
system to ensure its long-term sustainability. At policy
level, it is essential to strengthen the legislative and regu-
latory framework and financial support for ART phar-
macovigilance. Limitations in these account for much of
the weakness in the ART pharmacovigilance systems in
most LMICs [32].
The WHO recommendation to make dolutegravir ac-
cessible to all women regardless of reproductive poten-
tial or plans [8], which has now been adopted in Uganda
(although not included in original guidelines [13]),
would significantly alleviate equity concerns around
dolutegravir use in women [33]. However, community
perceptions of the teratogenicity of dolutegravir are un-
likely to completely disappear overnight and may con-
tinue to undermine uptake among women. Achieving
universal coverage of dolutegravir-based treatment
among women requires greater community awareness
and education. Such demand generation efforts should
be embedded in a comprehensive community engage-
ment approach that targets both HIV positive and nega-
tive persons to raise awareness and collate community
feedback. Engaging with men would be critical to enhan-
cing dolutegravir use among women due to the wide-
spread patriarchal norms in these societies [34].
Access to effective contraception continues to be crit-
ical to dolutegravir transition. The WHO 2019 guide-
lines, adopted by both South Africa and Uganda,
stipulate that women are informed about the risks asso-
ciated with dolutegravir use in pregnancy combined with
an offer of choice of contraception [8]. Evidence suggest
that low access to and uptake of effective contraceptive
methods among women living with HIV in LMICs,
linked with concerns about health risks relating to side
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effects, contraceptive failure arising from drug-drug in-
teractions with ARVs, and lack of contraception services
[35, 36] . There is the need for an improvement in the
availability of these contraception services combined
with health care worker and community-based interven-
tions to promote positive attitudes toward contraception
among women living with HIV. Integration of contra-
ception and ART services, as noted by the stakeholders,
is essential to effective transition. Although potentially
feasible and cost-efficient to implement in resource-
limited settings [37], integration was reported to be weak
in both South Africa and Uganda. Strengthening this
would require action at policy and service delivery levels,
including common guidelines and funding for both ser-
vices, increasing staffing for and training in contracep-
tion services, reorienting service delivery to create one-
stop centres for accessing both services, and improving
referral systems [38].
The choice-based approach to dolutegravir use among
women of childbearing age recommended by the WHO
[2, 8] and adopted by South African [14] and Ugandan
[13] ART guidelines, is necessary to promote women’s
autonomy and ART uptake and adherence, but may
undermine treatment harmonisation by requiring differ-
entiated service provision. Similar to previous observa-
tions [39], our findings suggest that actual
implementation of informed choice may be constrained
by widespread patriarchy, medical paternalism and high
illiteracy among women. Promoting informed choice at
the community level requires careful attention to cul-
tural sensitivities of empowering women to make their
own choices, while seeking to reorient the decision-
making relationship between women and their partners.
Health workers should also be enabled to support pa-
tients with decision-making through the provision of ad-
equate training and information. The complexity of
balancing the risks of dolutegravir in pregnancy against
the limited experience on choice-based ART service de-
livery, suggests the need for further support on how to
communicate these risks and choices. Further, improv-
ing the availability of a range of contraception options
and alternative ART regimens (e.g. efavirenz-based regi-
mens) would be key to enhancing choice and enabling
women to access their preferred treatments.
Our findings present several implications for key
health systems stakeholders. Policymakers and program-
mers need to strengthen supply chain capacity and in-
ternal stock management systems to ensure continuous
availability of ART and contraception commodities. The
pricing agreement on dolutegravir negotiated by
UNAIDS and other partners could be leveraged to im-
prove the availability of generic versions of dolutegravir-
based regimens [40]. They should also revise ART guide-
lines and simplify these to make them assessible to lower
cadre health workers, including ART prescribers learn-
ing about how to administer contraception services in
an integrated HIV – contraceptive service delivery
model. Donors and development partners need to grant
the opportunity (including financial and technical sup-
port) for health systems to adequately strengthen their
capacities and collate the necessary evidence to inform
the transition.
Limitations
The interviews were conducted at a time when the two
study countries had not started implementing the transi-
tion to dolutegravir-based regimens. Therefore, the find-
ings are based mainly on respondents’ perceptions of
anticipated challenges and outcomes rather than data
from the actual implementation of the transition. How-
ever, responses were mainly informed by participants’
depth of knowledge of the health systems and experience
of previous ART transitions, which would have strength-
ened the validity of the findings. The qualitative design
and small sample size of the study may have limited the
generalisability of the findings. Nevertheless, our use of
purposive sampling approach ensured that we were able
to capture views that were typical of the groups that the
respondents represented, and we reached thematic sat-
uration. Due to the exploratory design of the study we
were only able to provide a brief account of the issues
related to the transition and could not delve into greater
detail for each of them: each of the discussed topics
could merit a separate detailed analysis within specific
health system contexts. Some of the researchers (LM,
ML, AK) were members of the ART guidelines group of
their respective countries and provided guidance in iden-
tifying potential participants for the study which may
have influenced participants selection and the study
data. To minimise bias, their input to the study was lim-
ited to advising on the study design and discussing and
reviewing draft results; they neither participated as inter-
viewees or interviewers nor directly analysed the
transcripts.
Conclusion
Our findings demonstrate the complexity of transitioning
to dolutegravir-based regimens among women of child-
bearing potential in low-resource context. We observed
that despite numerous challenges to transition, driven in
part by the bottlenecks of the weak health systems of
LMICs and the rapid pace of change, that transition pro-
vides potential opportunities for strengthening contracep-
tive and pregnancy pharmacovigilance. The challenges of
transition are far-reaching and pervade different aspects of
the health system, suggesting the need for a multi-sectoral
effort to facilitate a successful rollout. This should include
extensive community engagement before and during the
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transition, as well as individual and institutional capacity
building, including comprehensive staff training and im-
provement in counselling and contraception services, with
focus on the strengthening of pregnancy pharmacovigi-
lance. Further observation and trial data are required to
better understand the safety of dolutegravir and facilitate
community uptake and adoption by health policy makers.
In future, health systems should develop mechanisms to
record experiences from previous transitions, in order to
inform future transitions and reduce repeated mistakes.
The push for transition to new ART drugs needs to recog-
nise the constraints of health systems in LMICs and to
allow for adequate planning and preparation prior to
transition.
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